a public good project by the
Synthesis
Company
of California

© 2026

Melissa Lochheed | doi.page

0 works0 citations0 h-index

Google Scholar OpenAlex

Melissa Lochheed

Novartis (United States)(US)Tris Pharma (United States)(US)

Research Areas

Bladder and Urothelial Cancer Treatments, Fibroblast Growth Factor Research, Urinary and Genital Oncology Studies

Most-Cited Works

→ Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma(2014)111 cited